News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cue Biopharma, Inc. - Common Stock
(NQ:
CUE
)
0.2580
-0.0120 (-4.44%)
Streaming Delayed Price
Updated: 2:57 PM EDT, Mar 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cue Biopharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
7 High-Potential Penny Stocks in the Biotech Sector
↗
May 04, 2023
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider.
Via
InvestorPlace
Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors
April 25, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
April 12, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Earnings Perspective: Return On Capital Employed
↗
March 22, 2023
Via
Benzinga
Cue Biopharma's Earnings Outlook
↗
March 20, 2023
Via
Benzinga
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
March 21, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 21, 2023
↗
March 21, 2023
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.20 per share on revenue of $41.75 million.
Via
Benzinga
Cue Biopharma to Host Business Update Call and Webcast
March 15, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences
March 01, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
February 22, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting
February 16, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board
February 16, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at Two February 2023 Scientific Conferences
February 01, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Announces Chief Medical Officer Transition
January 23, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
November 22, 2022
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)
November 17, 2022
Via
ACCESSWIRE
Cue Biopharma Reports Third Quarter 2022 Financial Results
November 14, 2022
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
November 14, 2022
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 10, 2022
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
November 09, 2022
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
November 07, 2022
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
↗
October 24, 2022
Good morning, traders! We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning!
Via
InvestorPlace
Why Soluna Holdings Shares Are Trading Sharply Lower; Here Are 38 Stocks Moving Premarket
↗
October 24, 2022
Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) rose 70.8% to $0.41 in pre-market trading. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation.
Via
Benzinga
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 05, 2022
From
Cue Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
October 04, 2022
Gainers
Via
Benzinga
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
↗
October 04, 2022
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday.
Via
Benzinga
Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
October 04, 2022
From
Cue Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
September 01, 2022
Via
Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
↗
August 22, 2022
Via
Benzinga
Cue Biopharma Shares Decline Following Initial-Stage Metastatic Cancer Study Kicks-off
↗
August 22, 2022
Cue Biopharma (NASDAQ: CUE) has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102 for the treatment of patients with Wilms' Tumor 1 (WT1)-positive recurrent/metastatic...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Close
